Quintiles Transitional Holdings (NYSE:Q) : Zacks Investment Research ranks Quintiles Transitional Holdings (NYSE:Q) as 3, which is a Hold recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 1.65, which indicates as a Buy.
Quintiles Transitional Holdings (NYSE:Q) : The most positive equity analysts on Quintiles Transitional Holdings (NYSE:Q) expects the shares to touch $83, whereas, the least positive believes that the stock will trade at $62 in the short term. The company is covered by 10 Wall Street Brokerage Firms. The average price target for shares are $74.55 with an expected fluctuation of $6.2 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Brokerage Firm, Wells Fargo, downgrades their rating on the shares of Quintiles Transitional Holdings (NYSE:Q). Wells Fargo has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 12, 2016.
Quintiles Transitional Holdings (NYSE:Q): stock turned positive on Tuesday. Though the stock opened at $61.92, the bulls momentum made the stock top out at $62.52 level for the day. The stock recorded a low of $61.78 and closed the trading day at $62.4, in the green by 1.76%. The total traded volume for the day was 1,042,022. The stock had closed at $61.32 in the previous days trading.
In an insider trading activity, The officer (EVP and COO), of Quintiles Transnational Holdings Inc., Gordon Kevin K had unloaded 24,000 shares at $66.41 per share in a transaction on June 9, 2016. The total value of transaction was $1,593,840. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.